阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌:德国真实世界队列研究结果
该研究纳入本中心2020年1月至2022年3月启动阿替利珠单抗联合贝伐珠单抗治疗的100例不可切除肝细胞癌患者,对照组为80例接受索拉非尼(n=43)或仑伐替尼(n=37)的晚期肝细胞癌患者。联合治疗组总生存期和无进展生存期显著更长,与III期数据相当,非病毒性肝细胞癌(58%)等亚组获益一致。基于ROC优化的中性粒细胞与淋巴细胞比值(NLR) cutoff 3.20是客观缓解率和无进展生存期最强的独立预测因素。
要点
- 阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌真实世界中显示出良好疗效和安全性,部分晚期肝硬化患者亦适用。
- NLR cutoff 3.20是客观缓解率和无进展生存期最强的独立预测因素,可能有助于患者选择。
- Child-Pugh B肝硬化患者客观缓解率相似但总生存期和无进展生存期较短,免疫治疗下肝功能保持显著更好。
核心结论
- 阿替利珠单抗联合贝伐珠单抗在不可切除肝细胞癌及部分晚期肝硬化患者的真实世界环境中显示出良好疗效和安全性。
- NLR能够预测阿替利珠单抗联合贝伐珠单抗治疗的应答,并可能指导患者选择。
研究设计与样本
- 本研究为本中心开展的真实世界队列研究,纳入2020年1月至2022年3月启动阿替利珠单抗联合贝伐珠单抗治疗的100例不可切除肝细胞癌患者。
- 对照组为80例接受索拉非尼(n=43)或仑伐替尼(n=37)系统治疗的晚期肝细胞癌患者。
主要发现
- 阿替利珠单抗联合贝伐珠单抗组的总生存期和无进展生存期显著更长,与III期数据相当。
- 客观缓解率、总生存期和无进展生存期的获益在各亚组中一致,包括非病毒性肝细胞癌(58%)。
- 基于ROC优化的NLR cutoff 3.20是客观缓解率和无进展生存期最强的独立预测因素。
- Child-Pugh B肝硬化患者接受免疫治疗时肝功能保持显著更好。
- Child-Pugh B肝硬化患者与肝功能保留患者相比客观缓解率相似,但总生存期和无进展生存期更短。
关键数值与推荐
- NLR cutoff 3.20为基于ROC优化的界值,是客观缓解率和无进展生存期最强的独立预测因素。
- 非病毒性肝细胞癌占58%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Phase III trials have established atezolizumab plus bevacizumab as the novel standard of care for patients with unresectable hepatocellular carcinoma (HCC). However, these trials raised concerns regarding treatment efficacy in non-viral HCC, and it remains unclear whether combination immunotherapy is safe and effective in patients with advanced cirrhosis. METHODS: One hundred patients with unresectable HCC initiated therapy with atezolizumab plus bevacizumab at our centre between January 2020 and March 2022. The control cohort consisted of 80 patients with advanced HCC who received either sorafenib (n = 43) or lenvatinib (n = 37) as systemic treatment. RESULTS: Overall survival (OS) and progression-free survival (PFS) were significantly longer within the atezolizumab/bevacizumab group and comparable to phase III data. The benefits in terms of increased objective response rate (ORR), OS and PFS were consistent across subgroups, including non-viral HCC (58%). The ROC-optimised neutrophil-to-lymphocyte ratio (NLR) cut-off of 3.20 was the strongest independent predictor of ORR and PFS. In patients with advanced cirrhosis Child-Pugh B, liver function was significantly better preserved with immunotherapy. Patients with Child-Pugh B cirrhosis showed similar ORR but shorter OS and PFS compared to patients with preserved liver function. CONCLUSIONS: Atezolizumab plus bevacizumab showed good efficacy and safety in patients with unresectable HCC and partially advanced liver cirrhosis in a real-world setting. Moreover, the NLR was able to predict response to atezolizumab/bevacizumab treatment and may guide patient selection.
引用
- Jost-Brinkmann F, Demir M, Wree A, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: Results from a German real-world cohort. Aliment Pharmacol Ther. 2023. PMID: 36883351. doi:10.1111/apt.17441
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。